Jones Financial Companies Lllp Has $10.05 Million Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Jones Financial Companies Lllp raised its stake in Becton, Dickinson and Company (NYSE:BDX) by 43.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 44,288 shares of the medical instruments supplier’s stock after purchasing an additional 13,387 shares during the quarter. Jones Financial Companies Lllp’s holdings in Becton, Dickinson and Company were worth $10,048,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in BDX. State Street Corp grew its stake in shares of Becton, Dickinson and Company by 0.8% in the third quarter. State Street Corp now owns 13,953,116 shares of the medical instruments supplier’s stock valued at $3,364,096,000 after buying an additional 106,616 shares in the last quarter. Geode Capital Management LLC lifted its stake in Becton, Dickinson and Company by 1.8% in the third quarter. Geode Capital Management LLC now owns 6,285,513 shares of the medical instruments supplier’s stock valued at $1,510,050,000 after acquiring an additional 111,101 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Becton, Dickinson and Company by 9.4% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier’s stock valued at $1,293,635,000 after acquiring an additional 460,440 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Becton, Dickinson and Company by 79.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock worth $720,089,000 after purchasing an additional 1,317,723 shares during the last quarter. Finally, Nordea Investment Management AB raised its holdings in shares of Becton, Dickinson and Company by 31.0% in the 4th quarter. Nordea Investment Management AB now owns 2,844,566 shares of the medical instruments supplier’s stock valued at $647,082,000 after purchasing an additional 673,568 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

BDX opened at $228.40 on Tuesday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $251.99. The firm has a market cap of $65.58 billion, a P/E ratio of 37.94, a price-to-earnings-growth ratio of 1.63 and a beta of 0.40. The business’s fifty day moving average is $233.12 and its 200-day moving average is $232.98.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Sell-side analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company declared that its Board of Directors has approved a share buyback plan on Tuesday, January 28th that permits the company to repurchase 10,000,000 shares. This repurchase authorization permits the medical instruments supplier to purchase shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be paid a $1.04 dividend. The ex-dividend date is Monday, March 10th. This represents a $4.16 annualized dividend and a dividend yield of 1.82%. Becton, Dickinson and Company’s payout ratio is 69.10%.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 700 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $227.99, for a total value of $159,593.00. Following the transaction, the director now owns 36,033 shares in the company, valued at $8,215,163.67. The trade was a 1.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jeffrey William Henderson bought 1,500 shares of the company’s stock in a transaction dated Monday, February 10th. The stock was bought at an average cost of $233.62 per share, with a total value of $350,430.00. Following the acquisition, the director now directly owns 8,015 shares of the company’s stock, valued at approximately $1,872,464.30. The trade was a 23.02 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders sold 10,544 shares of company stock valued at $2,370,309. Corporate insiders own 0.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on BDX shares. StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Tuesday, February 25th. Barclays upped their price objective on Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Finally, Piper Sandler boosted their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research report on Tuesday, January 28th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Becton, Dickinson and Company has an average rating of “Moderate Buy” and an average price target of $278.29.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.